CirrusDx Now Offers Susceptibility Testing for Blujepa® (gepotidacin), a Recently Approved Antibiotic for Urinary Tract Infections
New capability gives clinicians the data they need to evaluate gepotidacin as a treatment option for patients with uncomplicated UTIs. ROCKVILLE, Md., June 2, 2026 /PRNewswire/ -- CirrusDx, Inc. (CirrusDx), an infectious disease laboratory and diagnostics company, today announced it now...
New capability gives clinicians the data they need to evaluate gepotidacin as a treatment option for patients with uncomplicated UTIs. ROCKVILLE, Md., June 2, 2026 /PRNewswire/ -- CirrusDx, Inc. (CirrusDx), an infectious disease laboratory and diagnostics company, today announced it now...
Summary aggregated from PR Newswire's public RSS feed. The full reporting belongs to PR Newswire — please read it on their site.